Oncotelic Therapeutics, Inc.·Healthcare

NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will formally introduce its Deciparticle™ nanomedicine platform and present its advancing clinical pipeline at BIO-Europe Spring 2026, where the company has been selected as a Presenting Company.

AGOURA HILLS, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will present new data on everolimus toxicology, focusing on tissue concentration–driven effects, at the upcoming Society of Toxicology (SOT) 2026 Annual Meeting and ToxExpo, taking place March 22–25, 2026, in San Diego, California.
Oncotelic Therapeutics (OTCMKTS:OTLC - Get Free Report) and Lexicon Pharmaceuticals (NASDAQ: LXRX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk. Profitability This table compares Oncotelic Therapeutics and

AUSTIN, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC). To hear the NetworkNewsAudio version, visit https://nnw.fm/hsKrq To read the original editorial, visit https://nnw.fm/IA5ih Platforms supported by existing human data also carry valuation advantages.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Healthcare
Biotechnology
26
1993-08-26
-0.59